On the continued benefit of antipsychotics after the first episode of schizophrenia

René S. Kahn

doi:10.1176/appi.ajp.2018.18060639

On the continued benefit of antipsychotics after the first episode of schizophrenia

René S. Kahn

Research output: Contribution to journal › Editorial

1 Scopus citations

Original language	English
Pages (from-to)	712-713
Number of pages	2
Journal	American Journal of Psychiatry
Volume	175
Issue number	8
DOIs	https://doi.org/10.1176/appi.ajp.2018.18060639
State	Published - Aug 2018

Access to Document

10.1176/appi.ajp.2018.18060639

Cite this

@article{5d6f30b170c84b53b6e355ee024cad9c,

title = "On the continued benefit of antipsychotics after the first episode of schizophrenia",

author = "Kahn, {Ren{\'e} S.}",

note = "Funding Information: From the Department of Psychiatry, Icahn School of Medicine, New York. Address correspondence to Dr. Kahn (rene.kahn@mssm.edu). Dr. Kahn has received grant support from Teva, consulting fees from Alkermes, Lundbeck, Otsuka, Merck, Minerva Neuroscience, and Roche, and speaking fees from Janssen-Cilag, Lundbeck, and Otsuka. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.",

year = "2018",

month = aug,

doi = "10.1176/appi.ajp.2018.18060639",

language = "English",

volume = "175",

pages = "712--713",

journal = "American Journal of Psychiatry",

issn = "0002-953X",

publisher = "American Psychiatric Association",

number = "8",

}

TY - JOUR

T1 - On the continued benefit of antipsychotics after the first episode of schizophrenia

AU - Kahn, René S.

N1 - Funding Information: From the Department of Psychiatry, Icahn School of Medicine, New York. Address correspondence to Dr. Kahn (rene.kahn@mssm.edu). Dr. Kahn has received grant support from Teva, consulting fees from Alkermes, Lundbeck, Otsuka, Merck, Minerva Neuroscience, and Roche, and speaking fees from Janssen-Cilag, Lundbeck, and Otsuka. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.

PY - 2018/8

Y1 - 2018/8

UR - http://www.scopus.com/inward/record.url?scp=85050974629&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2018.18060639

DO - 10.1176/appi.ajp.2018.18060639

M3 - Editorial

C2 - 30064241

AN - SCOPUS:85050974629

SN - 0002-953X

VL - 175

SP - 712

EP - 713

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

IS - 8

ER -